Radiation plus immunotherapy and chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that is locally advanced (has spread to nearby lymph nodes but not to distant organs) and can be surgically removed.
- You are between 18 and 75 years old and have not received any prior cancer treatment for this condition.
- Your overall health is good, with a performance status of 0 or 1 (meaning you can carry out daily activities without much help).
- You have adequate organ function, such as normal blood counts, liver and kidney function, and no uncontrolled infections.
- You have not been treated with immunotherapy drugs like PD-1 inhibitors before, and you do not have an active autoimmune disease or other serious medical conditions like recent heart problems or another cancer within the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.